Back to search

Peptide record

TPDB18561

Antibacterial Antiviral Toxicity modified_plain modified
42 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB18561
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 42-aa modified multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGX
Physicochemical Analysis
C184H311N53O68
CHMFPTWY
NILS
4353.81
3.96
3
7
15
-4
14.03
-0.219
118.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: >10 hour
0
0.00
12
Residue Composition
number
2
A
1
R
5
N
3
D
0
C
4
E
2
Q
4
G
0
H
5
I
5
L
2
K
0
M
0
F
0
P
5
S
0
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 2 R: 1 N: 5 D: 3 C: 0 E: 4 Q: 2 G: 4 H: 0 I: 5 L: 5 K: 2 M: 0 F: 0 P: 0 S: 5 T: 0 W: 0 Y: 0 V: 3
Chemical Descriptors
42
C184H311N53O68
4353.81
3.96
-4
14.03
-0.219
Evidence Records 4 records
Evidence 1 Activity

Activity

18% Cytotoxicity
Toxicity
10 µM
Cytotoxic
18% Cytotoxicity | 10 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020
Evidence 2 Activity

Activity

12% Cytotoxicity
Toxicity
1 µM
Cytotoxic
12% Cytotoxicity | 1 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020
Evidence 3 Activity

Activity

30% Cytotoxicity
Toxicity
10 µM
Cytotoxic
30% Cytotoxicity | 10 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020
Evidence 4 Activity

Activity

25% Cytotoxicity
Toxicity
1 µM
Cytotoxic
25% Cytotoxicity | 1 | µM | target cell: Human airway epithelial cells

Target

Human airway epithelial cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020